javier gallastegui

Bionaturis turns two years on the MAB: 3, 2, 1… ready to take off!

It is just two years ago that Bionaturis started quoting on the Spanish Alternative Stock Market (MAB). On 26th January, 2012; the managers of the company began the new age ringing the bell at the opening session of its quotation. Since then, Bionaturis has had an exponential growth and the future prospects can’t be better, as our general manager, Javier Gallastegui, states.

-How do you remember the IPO process and Bionaturis’ opening day at MAB?

-My arrival at the company was in a key moment because I started to work at Bionaturis very little time before trading at the MAB, so, the process was already ongoing. About that day, I remember moments of great happiness, with emotion and pride shared with our team, which was there all together. We realized how well-known people both in the industry and the financial sector, among them my closest guests, looked with admiration at such an important milestone we were achieving.  Among them Emilio Moraleda, who joined our Board of Directors shortly after that.

-What has the MAB provided to Bionaturis’ development these two years?

-Apart from the logical contribution as source of capital income, for our development and current position being a transparent trading company for the lens of our multinational customers, our investors and the stock market is very important. The experience and the balance, according to facts and results, can’t be more positive: the company market cap has more than doubled since then and so our multinational clients and product portfolio as well. The future is bright ahead of us.

-How do you describe the current situation of Bionaturis on the MAB?

-With a great strength, and as it’s usual to say in these cases, I am not the person who […]

A veterinarian multinational company will test the Bionaturis vaccine against nematodes in livestock

Bionaturis (BNT-MAB), an international reference company developing biological vaccines, has signed a contract with a multinational veterinarian company that will test the efficacy and safety of a vaccine to prevent livestock to be infected by intestinal nematodes -helminthes-. This agreement endorses Bionaturis strategic position as a supplier of vaccines for the veterinarian industry.

These gastrointestinal parasites cause annual losses of 3,000 million Euros in the livestock industry. To combat their effects, companies are using chemical endoparasticides that gradually lose efficacy due to growing phenomena of resistance. For this reason among others, governments and sectorial organizations are recommending a reduction of their use. In preliminary in-vivo tests, Bionaturis vaccine has shown superb protection against the types of helminthes that cause more problems and phenomena of resistance in the field. This product, encoded by the company as BNT004, is a first-in-class preventive treatment, and it could become a real and safe option against the most serious cases of resistance.

Efficacy higher than 65% in mice and lamb trials

BNT004 has already been tested in mice and lamb trials, showing protection values higher than 65%, in all cases, about the reduction of the number of parasites in vaccinated animals versus control. Besides, the vaccine is 100% safe and the treated animals did not show any symptomatology. As outstanding outcome for the livestock industry, challenged and vaccinated animals did not show a loss of weight versus control animals, whereas the challenged un-vaccinated animals did.

BNT004 is protected by a patent application of University of Granada (UGR), active in the main traditional veterinarian markets, out-licensed exclusively to Bionaturis back in 2012. Next trials will be made in the multinational company facilities and they will be finished in the first semester of 2014.

Javier Gallestegui, […]

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.